Valley Brook Capital Group Inc. Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

Valley Brook Capital Group Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 8.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,025 shares of the company’s stock after selling 1,046 shares during the period. Johnson & Johnson comprises approximately 1.4% of Valley Brook Capital Group Inc.’s holdings, making the stock its 19th largest holding. Valley Brook Capital Group Inc.’s holdings in Johnson & Johnson were worth $1,828,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock worth $38,800,371,000 after buying an additional 1,170,120 shares in the last quarter. Northern Trust Corp boosted its holdings in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Johnson & Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after purchasing an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Johnson & Johnson by 2.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock worth $3,031,955,000 after purchasing an additional 448,666 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $176.76 on Friday. The stock’s 50-day moving average is $161.28 and its two-hundred day moving average is $158.39. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $177.27. The company has a market cap of $425.70 billion, a price-to-earnings ratio of 18.90, a price-to-earnings-growth ratio of 2.25 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the business posted $2.82 EPS. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on JNJ. Guggenheim reiterated a “neutral” rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Finally, UBS Group upped their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.